New drug shows promise in reducing NMOSD attacks
NCT ID NCT04201262
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested a drug called ravulizumab in 58 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the nerves and spinal cord. The goal was to see if the drug could prevent or reduce relapses (sudden worsening of symptoms). Participants received ravulizumab and were compared to a placebo group from a previous study. The results help doctors understand if this treatment is safe and effective for controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Fort Collins, Colorado, 80528, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Jackson, Mississippi, 39216, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Cincinnati, Ohio, 45219, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Camperdown, 2050, Australia
-
Research Site
Fitzroy, 3065, Australia
-
Research Site
Vienna, 1090, Austria
-
Research Site
Burnaby, British Columbia, V5G 2X6, Canada
-
Research Site
Aarhus, 8200, Denmark
-
Research Site
Strasbourg, 67098, France
-
Research Site
Berlin, 10117, Germany
-
Research Site
Leipzig, 04103, Germany
-
Research Site
München, 81675, Germany
-
Research Site
Cefalù, 90015, Italy
-
Research Site
Gallarate, 21013, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Roma, 00133, Italy
-
Research Site
Rome, 00178, Italy
-
Research Site
Chiba, 260-0877, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Kawagoe-shi, 350-8550, Japan
-
Research Site
Niigata, 951-8585, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Sendai, 983-8512, Japan
-
Research Site
Katowice, 40-571, Poland
-
Research Site
Lódz, 90-324, Poland
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 143-729, South Korea
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Oxford, OX3 9DU, United Kingdom
Conditions
Explore the condition pages connected to this study.